| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 340,200 | 264,000 | ||
| Available-for-sale debt securities | 774,600 | 711,600 | ||
| Accounts receivable | 728,000 | 595,700 | ||
| Inventory | 69,300 | 56,900 | ||
| Prepaid expenses | 178,100 | - | ||
| Other current assets | 68,200 | 120,700 | ||
| Total current assets | 2,158,400 | 1,748,900 | ||
| Deferred tax assets | 368,500 | 536,800 | ||
| Available-for-sale debt securities | 998,500 | 873,800 | ||
| Right-of-use assets | 468,900 | 492,300 | ||
| Equity investments | 118,100 | 87,500 | ||
| Property and equipment, net | 97,300 | 91,700 | ||
| Intangible assets, net | 35,700 | 37,200 | ||
| Other noncurrent assets | 20,300 | 21,600 | ||
| Total assets | 4,265,700 | 3,889,800 | ||
| Accounts payable and accrued liabilities | 584,300 | 489,500 | ||
| Other current liabilities | 53,700 | 56,800 | ||
| Total current liabilities | 638,000 | 546,300 | ||
| Noncurrent operating lease liabilities | 428,400 | 439,100 | ||
| Other noncurrent liabilities | 195,700 | 210,100 | ||
| Total liabilities | 1,262,100 | 1,195,500 | ||
| Common stock, 0.001 par value 220.0 shares authorized 99.7 and 99.4 shares issued and outstanding, respectively | 100 | 100 | ||
| Additional paid-in capital | 2,696,300 | 2,597,200 | ||
| Accumulated other comprehensive income | 13,200 | 12,500 | ||
| Retained earnings | 294,000 | 84,500 | ||
| Total stockholders equity | 3,003,600 | 2,694,300 | ||
| Total liabilities and stockholders equity | 4,265,700 | 3,889,800 | ||
NEUROCRINE BIOSCIENCES INC (NBIX)
NEUROCRINE BIOSCIENCES INC (NBIX)